OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Given Consensus Recommendation of “Hold” by Brokerages

Shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) have been assigned a consensus recommendation of “Hold” from the five research firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $6.3333.

Several equities analysts have recently issued reports on OKYO shares. HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of OKYO Pharma in a report on Thursday, January 29th. Piper Sandler assumed coverage on OKYO Pharma in a report on Friday, February 20th. They issued an “overweight” rating and a $7.00 price target for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of OKYO Pharma in a report on Tuesday, April 21st.

OKYO Pharma Price Performance

Shares of OKYO stock opened at $1.62 on Wednesday. The business has a 50-day simple moving average of $1.62 and a 200-day simple moving average of $1.96. OKYO Pharma has a 52-week low of $1.34 and a 52-week high of $3.35.

Hedge Funds Weigh In On OKYO Pharma

Large investors have recently bought and sold shares of the business. Citadel Advisors LLC acquired a new position in OKYO Pharma in the 3rd quarter worth about $31,000. XTX Topco Ltd acquired a new position in OKYO Pharma in the 4th quarter worth about $36,000. Finally, Renaissance Technologies LLC raised its holdings in OKYO Pharma by 235.0% in the 4th quarter. Renaissance Technologies LLC now owns 138,000 shares of the company’s stock worth $286,000 after purchasing an additional 96,800 shares during the period. Institutional investors and hedge funds own 2.97% of the company’s stock.

OKYO Pharma Company Profile

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.